UY39396A - Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov-2 y/o la prevención de la infección por coronavirus relacionada con el sarscov-2 - Google Patents

Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov-2 y/o la prevención de la infección por coronavirus relacionada con el sarscov-2

Info

Publication number
UY39396A
UY39396A UY0001039396A UY39396A UY39396A UY 39396 A UY39396 A UY 39396A UY 0001039396 A UY0001039396 A UY 0001039396A UY 39396 A UY39396 A UY 39396A UY 39396 A UY39396 A UY 39396A
Authority
UY
Uruguay
Prior art keywords
sarscov
induction
prevention
aav5
cov
Prior art date
Application number
UY0001039396A
Other languages
English (en)
Inventor
Dmitry Valentinovich Morozov
Pavel Andreevich Iakovlev
Pavel Mikhailovich Gershovich
Alexander Vladimirovich Prokofyev
Anna Nikolaevna Strelkova
Natalia Aleksandrovna Spirina
Diana Aleksandrovna Kondinskaia
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020128658A external-priority patent/RU2783313C1/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of UY39396A publication Critical patent/UY39396A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invención refiere a un dominio de unión a receptor recombinante aislado de la glicoproteína S (RBD-S) de SARS-CoV-2, a un ácido nucleico que codifica RBD-S de SARS-CoV-2, a un casete de expresión y un vector basado en el mismo, a un virus basado en AAV5 recombinante (virus adenoasociado serotipo 5) para la inducción de inmunidad específica al SARS-CoV-2 y / o la prevención de dicha infección, a un AAV5 -vacuna basada en la inducción de inmunidad específica al SARS-CoV-2 y / o prevención de la infección por coronavirus relacionada con el SARS-CoV-2.
UY0001039396A 2020-08-28 2021-08-27 Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov-2 y/o la prevención de la infección por coronavirus relacionada con el sarscov-2 UY39396A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020128658A RU2783313C1 (ru) 2020-08-28 Вакцина на основе AAV5 для индукции специфического иммунитета к вирусу SARS-CoV-2 и/или профилактики коронавирусной инфекции, вызванной SARS-CoV-2

Publications (1)

Publication Number Publication Date
UY39396A true UY39396A (es) 2022-02-25

Family

ID=80353679

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039396A UY39396A (es) 2020-08-28 2021-08-27 Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov-2 y/o la prevención de la infección por coronavirus relacionada con el sarscov-2

Country Status (13)

Country Link
US (1) US20230321220A1 (es)
EP (1) EP4185323A1 (es)
JP (1) JP2023540085A (es)
KR (1) KR20230092880A (es)
CN (1) CN116438192A (es)
AR (1) AR123369A1 (es)
AU (1) AU2021331947A1 (es)
BR (1) BR112023003614A2 (es)
CA (1) CA3191194A1 (es)
IL (1) IL300738A (es)
UY (1) UY39396A (es)
WO (1) WO2022045935A1 (es)
ZA (1) ZA202301438B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117511968A (zh) * 2023-11-06 2024-02-06 军事科学院军事医学研究院军事兽医研究所 表达SARS-CoV-2的S、E和M蛋白的重组金丝雀痘病毒及其构建方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023219533A1 (ru) * 2022-05-11 2023-11-16 Общество С Ограниченной Ответственностью "Герофарм" Аденоассоциированный вирусный вектор на основе серотипа aav.php.b и его применение

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111533809A (zh) * 2020-04-21 2020-08-14 中国科学院武汉病毒研究所 针对新型冠状病毒的亚单位疫苗及应用
RU2723008C9 (ru) * 2020-05-19 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Способ получения штамма клеток яичника китайского хомячка, продуцента рекомбинантного белка RBD вируса SARS-CoV-2, штамм клеток яичника китайского хомячка, продуцент рекомбинантного белка RBD вируса SARS-CoV-2, способ получения рекомбинантного белка RBD вируса SARS-CoV-2, тест-система для иммуноферментного анализа сыворотки или плазмы крови человека и ее применение
CN111560354B (zh) * 2020-05-22 2022-07-19 中国人民解放军总医院第五医学中心 重组新型冠状病毒及其制备方法和应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117511968A (zh) * 2023-11-06 2024-02-06 军事科学院军事医学研究院军事兽医研究所 表达SARS-CoV-2的S、E和M蛋白的重组金丝雀痘病毒及其构建方法和应用

Also Published As

Publication number Publication date
AU2021331947A9 (en) 2023-07-06
BR112023003614A2 (pt) 2023-03-28
AU2021331947A1 (en) 2023-05-04
US20230321220A1 (en) 2023-10-12
WO2022045935A1 (en) 2022-03-03
IL300738A (en) 2023-04-01
CN116438192A (zh) 2023-07-14
CA3191194A1 (en) 2022-03-03
EP4185323A1 (en) 2023-05-31
KR20230092880A (ko) 2023-06-26
ZA202301438B (en) 2023-09-27
AR123369A1 (es) 2022-11-23
JP2023540085A (ja) 2023-09-21

Similar Documents

Publication Publication Date Title
UY39582A (es) Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov- 2 y/o la prevención de la infección por coronavirus relacionada con el sarscov- 2
UY39396A (es) Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov-2 y/o la prevención de la infección por coronavirus relacionada con el sarscov-2
BR112022009895A2 (pt) Construtos de terapia de gene de microdistrofina e usos dos mesmos
CO2023001072A2 (es) Vacuna combinada de sars-cov-2 e influenza
CY1119052T1 (el) Νεες φαρμακοτεχνικες μορφες εμβολιου που περιλαμβανουν ανοσοενισχυτικα που περιεχουν σαπωνινη
PE20181168A1 (es) VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
BR112018011975A2 (pt) composições úteis no tratamento de atrofia muscular espinhal
BR112022016346A2 (pt) Vacina ncov-2019 (sars-cov-2)
BR112022014884A2 (pt) Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave
EA201170812A1 (ru) Способы и композиции для применения вакцины против кокцидиоза
BR112012031211A2 (pt) métodos e vacina para reduzir a infecção causada pelo campylobacter
BR112022016891A2 (pt) Vacina contra a infecção por vírus da peste suína africana
MX2021012311A (es) Variantes de capsides de aav para liberacion intravitrea.
CO2017001614A2 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
BR112018068890A2 (pt) dna polimerases marinhas
CL2022000161A1 (es) Vacuna contra la peste porcina africana
BR112018012523A2 (pt) cabo com reforço de borracha e produto de borracha usando o mesmo
MX9304349A (es) Vacuna antirrabica no virulenta.
MX2022015489A (es) Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
ATE493146T1 (de) Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
BR112022022263A2 (pt) Tratamento de infecções virais
BR112022024911A2 (pt) Materiais e métodos para inibir uma infecção viral, incluindo uma infecção por coronavírus
BR112022016604A2 (pt) Compostos para uso em infecções virais
MX2022004059A (es) Utilizacion de un agente para la induccion de inmunidad especifica contra el virus del sindrome respiratorio agudo severo sars-cov-2 en ni?os.
BR112023026164A2 (pt) Bacteriófagos contra enterococci resistentes à vancomicina